Progression‐free survival · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy probably leads to lower progression‐free survival (PFS) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Psychosocial interventions (cognitive behavioural therapy,… led to lower pain intensity (long term) compared with usual care (conservative treatment: education, counselling,…; GRADE not reported.
1 finding from 1 review
Muscle palpation pain (long term) · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Psychosocial interventions (cognitive behavioural therapy,… showed no clear difference in muscle palpation pain (long term) compared with usual care (conservative treatment: education, counselling,…; GRADE not reported.
1 finding from 1 review
Depression (long term) · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Psychosocial interventions (cognitive behavioural therapy,… led to lower depression (long term) compared with usual care (conservative treatment: education, counselling,…; GRADE not reported.
1 finding from 1 review
Reduction in pain intensity · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Psychosocial interventions (cognitive behavioural therapy,… led to higher pain intensity (short term) compared with usual care (conservative treatment: education, counselling,…; GRADE not reported.
1 finding from 1 review
Pain severity - impact: activity interference / disability (long term) · Adults over 18 years of age with chronic orofacial pain (temporomandibular disorder (TMD))
Psychosocial interventions (cognitive behavioural therapy,… led to lower pain severity - impact: activity interference / disability (long term) compared with usual care (conservative treatment: education, counselling,…; GRADE not reported.
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review